Selecting I-O Agents and Combinations for Patients With RCC
Robert A. Figlin, MD director, division of hematology/oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the considerations behind selecting an immune-oncology agent for the treatment of patients with renal cell carcinoma.
Robert A. Figlin, MD director, division of hematology/oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the considerations behind selecting an immuno-oncology (I-O) agent for the treatment of patients with renal cell carcinoma (RCC).
As physicians are becoming more comfortable using these agents both alone and in combination with targeted therapies, the key to selecting agents for these patients will vary, Figlin says. Some endpoints to consider may include objective response rate, overall survival, progression-free survival, adverse events, among many others.
The conversations between physicians and patients are different now than they were in the past, Figlin notes. These therapies can not only improve quality of life but also shrink tumors enough that there may be opportunities to go off treatment.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
